N/A N=918 Expectation of Unpleasant Events in Anxiety Disorders
Anxiety Disorders
Primary: Change in Percent of Correct Button Presses During Threat Compared to the Safe Condition (AAST) — -0.016; 0.008 Percentage of accurate responses
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 A Unified Treatment for Anxiety Disorders
Emotional Disorders · Anxiety Disorders
Primary: Anxiety Disorders Interview Schedule for DSM-IV — 5.23; 5.09; 3.18; 5.14 score on a scale
Phase 2 N=41 PH94B in the Treatment of Adjustment Disorder With Anxiety
Adjustment Disorder With Anxious Mood
Primary: Hamilton Anxiety Scale (HAM-A) Score — -12.5; -12.6 score on a scale — p=0.9338
N/A N=151 Clinical Management of Anxiety and Access to Health Care
Dental Anxiety
Primary: Change in Modified Dental Anxiety Scale — 19.5; 19.6; 15.4; 17.6 units on a scale — p=<0.05
N/A N=167 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
Autism Spectrum Disorders · Autism · Asperger's Syndrome
Primary: Change From Baseline in Anxiety Severity on the Pediatric Anxiety Rating Scale After 16 Weeks of Treatment. — 3.43; 3.47; 3.28; 2.13 units on a scale
Phase 4 N=1,004 Primary Care Intervention Strategy for Anxiety Disorders
Post-traumatic Stress Disorder · Generalized Anxiety Disorder · Panic Disorder
Primary: BSI-12 (Anxiety and Somatization Subscales) — 325; 258 number of responders
Phase 4 N=60 Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
Anxiety Disorder
Primary: Magnitude of Startle Reflex During Safe Condition — 42.2880893; 42.39801; 43.61243; 44.1886408 millivolts (mV)
N/A N=56 Anxiety in Older Veterans
Anxiety Disorders
Primary: Change in Anxiety Symptoms — 1.77; -2.42 units on a scale
N/A N=23 Treating Phobia With Multivoxel Neuro-reinforcement
Phobia
Primary: Change in Amygdala Reactivity — -.691; -.827; -.278 Beta Coefficient
Phase 4 N=390 Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders
Anxiety
Primary: Change From Baseline in the Mean HAM-A Score at 12 Weeks of Treatment: 1. Group 1 (Tenoten®, 4 Tablets a Day); 2. Group 3 (Tenoten®, 8 Tablets a Day). — 18.81; 18.38…
N/A N=18 Novel Anxiety Treatment
Cognitive Training · Anxiety Disorders
Primary: Change in Symptoms of Anxiety Based on Screen for Anxiety and Related Disorders (SCARED) Parent Report at Baseline and Post Assessment — -20.4; -21.12 units on a scale
N/A N=48 Attention Disengagement Training for Social Phobia
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 68.1; 74.5; 60.0; 46.1 units on a scale
Phase 4 N=418 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
N/A N=141 Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13 — -9.44; -5.37 units on a scale
N/A N=1,418 Effects of Arousal and Stress in Anxiety
Healthy Volunteers
Primary: Go Correct Hits Followed by Button Press — 90.9; 91.6 Percentage of correct responses
Phase 3 N=81 Psychosocial and Medication Treatment for Anxiety in Alcoholism
Alcohol-Related Disorders · Anxiety Disorders
Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale
Phase 3 N=224 PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
Social Anxiety Disorder
Primary: Subjective Units of Distress Scale (SUDS) Score — 77.7; 78.2; 62.3; 61.3 score on a scale — p=.5063
N/A N=51 Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
Anxiety · Healthy Volunteers
Primary: Difference in Learning Rate — 0.009; 0.0058 unitless
N/A N=1,063 Brain Imaging Changes in Fear and Anxiety
Anxiety Disorders · Fear
Primary: Average Correlations Between Average Time Series - Left & Right Hemisphere of the Brain — 0.9; 0.92 correlation coefficient (r) — p=< 0.001
N/A N=27 Strategies for Treating Anxiety Research Study
Anxiety Disorders · Anxiety
Primary: Number of Patient Participants Retained in the Intervention (Out of All of Those Enrolled), as Measured by Completion to All Study Treatment Visits. — 17 Participants
Phase 3 N=265 Transdiagnostic Cognitive Behavioral Treatment for Anxiety
Anxiety Disorders
Primary: CRIS-EPS: Comparison of Extent of Participation Scores Among iCBT, sCBT, and TAU Groups From Baseline to 1, 3, and 6 Month Follow Ups — 4.21; 4.18; 4.17; 4.52 score on a…
Phase 4 N=172 Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
Posttraumatic Stress Disorder · Anxiety Disorder
Primary: Change From Baseline Skin Conductance Response — .06; .17; -1.27; -.04 microSiemens — p=>.05
Phase 4 N=32 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity
Phase 4 N=42 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
Generalized Anxiety Disorder
Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…
Phase 2 N=151 A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 22.42; 24.26…
N/A N=76 A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: High End State Function — 56.52; 43.48; 56.52; 47.62 % people meeting high endstate status
N/A N=606 Stress, Sex, and the Generalization of Fear
Psychological Stress
Primary: Fear-potentiated Startle Responses to the CS+ and CS- During Acquisition — 52.059; 19.162; 44.388; 9.732 Fear-potentiated startle (microvolts) — p=0.453
N/A N=15 Assessing Visual Processing in High Anxiety
Anxiety
Primary: Tolerability of the Micro Expression Training Task in Individuals With High Anxiety — 5; 6 Participants
Phase 2 N=33 Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale. — 11.62; 14.04 units on a scale — p=.04
N/A N=40 Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)
Anxiety Disorders
Primary: Hamilton Anxiety Rating Scale — 5; 6 Participants